CA3018635C - Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation - Google Patents

Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation Download PDF

Info

Publication number
CA3018635C
CA3018635C CA3018635A CA3018635A CA3018635C CA 3018635 C CA3018635 C CA 3018635C CA 3018635 A CA3018635 A CA 3018635A CA 3018635 A CA3018635 A CA 3018635A CA 3018635 C CA3018635 C CA 3018635C
Authority
CA
Canada
Prior art keywords
masitinib
pharmaceutically acceptable
acceptable salt
solvate
als
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3018635A
Other languages
English (en)
French (fr)
Other versions
CA3018635A1 (en
Inventor
Alain Moussy
Jean-Pierre Kinet
Colin Mansfield
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AB Science SA
Original Assignee
AB Science SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AB Science SA filed Critical AB Science SA
Publication of CA3018635A1 publication Critical patent/CA3018635A1/en
Application granted granted Critical
Publication of CA3018635C publication Critical patent/CA3018635C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA3018635A 2016-03-25 2017-03-24 Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation Active CA3018635C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16162490.3 2016-03-25
EP16162490 2016-03-25
PCT/EP2017/057134 WO2017162884A1 (en) 2016-03-25 2017-03-24 Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation

Publications (2)

Publication Number Publication Date
CA3018635A1 CA3018635A1 (en) 2017-09-28
CA3018635C true CA3018635C (en) 2023-09-26

Family

ID=55637258

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3018635A Active CA3018635C (en) 2016-03-25 2017-03-24 Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation

Country Status (20)

Country Link
US (1) US10092564B2 (https=)
EP (1) EP3240538B1 (https=)
JP (2) JP7250312B2 (https=)
KR (1) KR102293847B1 (https=)
CN (1) CN108883108B (https=)
AU (1) AU2017236177B2 (https=)
BR (1) BR112018069515A2 (https=)
CA (1) CA3018635C (https=)
DK (1) DK3240538T3 (https=)
EA (1) EA038531B1 (https=)
ES (1) ES2899929T3 (https=)
HU (1) HUE057398T2 (https=)
IL (1) IL261856B (https=)
MX (1) MX390495B (https=)
NZ (1) NZ745778A (https=)
PL (1) PL3240538T3 (https=)
PT (1) PT3240538T (https=)
SG (1) SG11201808106YA (https=)
SI (1) SI3240538T1 (https=)
WO (1) WO2017162884A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9925282B2 (en) 2009-01-29 2018-03-27 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
CA2889446C (en) 2012-10-25 2021-05-11 The General Hospital Corporation Combination therapies for the treatment of alzheimer's disease and related disorders
US10525005B2 (en) 2013-05-23 2020-01-07 The General Hospital Corporation Cromolyn compositions and methods thereof
AU2014340182B2 (en) 2013-10-22 2019-05-23 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
CA3033079A1 (en) * 2016-08-31 2018-03-08 The General Hospital Corporation Macrophages/microglia in neuro-inflammation associated with neurodegenerative diseases
BR112019009711A2 (pt) 2016-11-25 2019-08-13 Genuv Inc método de indução de neuro-regeneração, método de proteção de neurônios contra perda ou dano neuronal, método de prevenção ou tratamento de doença neurodegenerativa devido à perda ou dano neuronal, e método de triagem de candidatos de fármaco para o tratamento de doenças neurodegenerativas
MX394840B (es) * 2017-03-28 2025-03-24 Novartis Ag Nuevos metodos para el tratamiento de la esclerosis multiple.
CA3065365C (en) * 2017-05-30 2025-09-16 Deciphera Pharmaceuticals, Llc USE OF 1-[4-BROMO-5-[1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDINE-3-YL]-2-FLUOROPHENYL]-3-PHENYLUREA AND ITS ANALOGUES FOR THE TREATMENT OF CANCERS ASSOCIATED WITH GENETIC ABNORMALITIES IN THE PLATELET-DERIVED GROWTH FACTOR ALPHA RECEPTOR
KR102874471B1 (ko) 2018-03-05 2025-10-31 매사추세츠 아이 앤드 이어 인퍼머리 콜로니 자극 인자의 표적화에 의한 녹내장 및 시신경병증 치료법
KR20210071943A (ko) 2018-07-02 2021-06-16 더 제너럴 하스피탈 코포레이션 크로몰린 소듐 및 α-락토스의 분말화된 제형
WO2020123449A1 (en) 2018-12-10 2020-06-18 The General Hospital Corporation Cromolyn esters and uses thereof
CN112618717A (zh) * 2019-09-24 2021-04-09 北京大学深圳研究生院 Btk抑制剂用于治疗肌萎缩侧索硬化症的用途
CN115243681B (zh) * 2019-12-30 2024-08-16 德西费拉制药有限责任公司 1-(4-溴-5-(1-乙基-7-(甲氨基)-2-侧氧基-1,2-二氢-1,6-萘啶-3-基)-2-氟苯基)-3-苯基脲的组合物
EP4132507A4 (en) 2020-04-06 2024-05-15 The General Hospital Corporation Methods of treatment of coronavirus-induced inflammation conditions
WO2025113494A1 (zh) * 2023-11-27 2025-06-05 浙江径科医药有限公司 多环类化合物及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW225528B (https=) 1992-04-03 1994-06-21 Ciba Geigy Ag
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
CA2494695C (en) 2002-08-02 2011-04-05 Ab Science 2-(3-aminoaryl)amino-4-aryl-thiazoles and their use as c-kit inhibitors
US8450302B2 (en) 2002-08-02 2013-05-28 Ab Science 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors
NZ578944A (en) 2007-02-13 2011-03-31 Ab Science PROCESS FOR THE SYNTHESIS OF 2-AMINOTHIAZOLE COMPOUNDS SUCH AS 4-(4-Methyl-piperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-benzamide AS KINASE INHIBITORS
US8906357B2 (en) 2010-04-20 2014-12-09 Ab Science Treatment of multiple sclerosis with masitinib
KR101951220B1 (ko) 2011-07-13 2019-02-22 싸이토키네틱스, 인코포레이티드 조합 als 치료법
DK2903616T3 (da) * 2012-10-04 2018-01-29 Ab Science Anvendelse af masitinib i kombination med gemcitabin til behandling af en undergruppe af patienter, der lider af pankreascancer
WO2014145909A2 (en) * 2013-03-15 2014-09-18 Dana-Farber Cancer Institute, Inc. Pyrimido-diazepinone compounds and methods of treating disorders
US20160263110A1 (en) * 2013-11-04 2016-09-15 Ab Science Use of masitinib for treatment of amyotrophic lateral sclerosis

Also Published As

Publication number Publication date
EA201800499A1 (ru) 2019-03-29
JP2022037132A (ja) 2022-03-08
EP3240538B1 (en) 2021-09-29
BR112018069515A2 (pt) 2019-04-16
JP7250312B2 (ja) 2023-04-03
AU2017236177A1 (en) 2018-09-20
PL3240538T3 (pl) 2022-01-31
SG11201808106YA (en) 2018-10-30
JP2019515884A (ja) 2019-06-13
WO2017162884A1 (en) 2017-09-28
IL261856B (en) 2022-04-01
DK3240538T3 (da) 2021-12-06
IL261856A (en) 2018-10-31
NZ745778A (en) 2022-07-01
PT3240538T (pt) 2021-12-07
AU2017236177B2 (en) 2022-03-31
MX390495B (es) 2025-03-20
CN108883108A (zh) 2018-11-23
US10092564B2 (en) 2018-10-09
CN108883108B (zh) 2021-08-06
SI3240538T1 (sl) 2022-02-28
MX2018011349A (es) 2019-02-07
ES2899929T3 (es) 2022-03-15
EP3240538A1 (en) 2017-11-08
KR102293847B1 (ko) 2021-08-26
US20180117037A1 (en) 2018-05-03
CA3018635A1 (en) 2017-09-28
KR20180125966A (ko) 2018-11-26
HUE057398T2 (hu) 2022-05-28
EA038531B1 (ru) 2021-09-10

Similar Documents

Publication Publication Date Title
CA3018635C (en) Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation
US9078894B2 (en) Treatment of severe persistant asthma with masitinib
KR101571163B1 (ko) 멜라토닌 효능제 치료
ES2824552T3 (es) Método de tratamiento con tradipitant
WO2012059526A1 (en) Treatment of mastocytosis with masitinib
JP2020513005A (ja) Ｃｃｒ３阻害剤を用いて、加齢性機能障害を治療するための方法及び組成物
CN106714819A (zh) 治疗普拉德‑威利综合征的方法
US20170119760A1 (en) Use of masitinib for the treatment of progressive supranuclear palsy
US20230089715A1 (en) Masitinib for the treatment of a multiple sclerosis patient subpopulation
CN104220072B (zh) 利用氨基吡啶治疗中风相关的感觉运动损伤的方法
US20160263110A1 (en) Use of masitinib for treatment of amyotrophic lateral sclerosis
EP1496908B1 (en) Combination of glivec(sti571) with a cyclin-dependent kinase inhibitor, especially flavopiridol in the treatment of cancer
WO2022129410A1 (en) Masitinib for the treatment of alzheimer's disease
HK1261581B (zh) 马赛替尼用於治疗肌萎缩侧索硬化症患者亚群的用途
HK1261581A1 (en) Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation
EP4069230A1 (en) Use of masitinib for the treatment of eosinophilic asthma
WO2016071511A1 (en) Treatment of mast cell activation syndrome (mcas) with masitinib
JP2025087929A (ja) うつ病および／またはうつ状態の治療および／または予防用医薬
CA3000894A1 (en) Treatment of severe systemic mastocytosis with masitinib
LI Newsletter May 2018

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210928

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 8TH ANNIV.) - STANDARD

Year of fee payment: 8

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250311

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250311

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250311

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 9TH ANNIV.) - STANDARD

Year of fee payment: 9

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260316

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260316